UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan. uri icon

authors

  • Wong, Megan H
  • Yuan, Yuan
  • Mortimer, Joanne E
  • Jones, Veronica C
  • Yu, Wai
  • Bosserman, Linda D
  • Lavasani, Sayeh M
  • Patel, Niki
  • Mina S. Sedrak, MD, MS
  • Stewart, Daphne B
  • Waisman, James R

publication date

  • August 2024